Shanghai, July 16— The "Smart Integration of Industry and Talent" Nantong Biopharmaceutical Industry Cooperation and Matchmaking Event, co-hosted by the Organization Department of the Nantong Municipal Committee (Talent Office), the Nantong Municipal Administration for Market Regulation, and Nantong Industrial Holding Group, was successfully held in Shanghai.

As an emerging force in the biopharmaceutical sector, Westlake Pharma was invited to attend the event. During the signing ceremony, the company officially entered into strategic partnership agreements with the Nantong Industrial Holding Siyuan AI Pilot Fund and Nantong Haorui Venture Capital Partnership. This milestone not only injects robust capital momentum into Westlake Pharma but also marks the beginning of a new chapter in cross-regional industrial synergy.

 Dr. Liang Dongdong, General Manager and Head of R&D at Westlake Pharma, attending the signing ceremony

The event aimed to deepen industrial collaboration between Shanghai and Nantong, facilitating the cross-regional implementation of biopharmaceutical innovations. The gathering brought together government officials, including Li Ling, Vice Mayor of Nantong, and Shao Shuai, Vice President of Shanghai Pharmaceuticals Holding, alongside industry experts, investment institutions, and corporate representatives, to discuss the integrated upgrade of the Yangtze River Delta’s biopharmaceutical industry.

The convergence of life sciences and artificial intelligence is currently reshaping the pharmaceutical landscape. This strategic partnership underscores the strong confidence that these two major Nantong industrial funds have in Westlake Pharma’s capabilities in frontier technology exploration and commercial translation.

A view of the industry cooperation and matchmaking event

Since its inception in 2020, Westlake Pharma has been dedicated to the R&D of first-in-class drugs. With a forward-looking vision, the company has deeply integrated artificial intelligence with multidisciplinary drug discovery, driving a paradigm shift in pharmaceutical R&D.

Leveraging this successful partnership and the support of industrial policies, Westlake Pharma will continue to increase its R&D investment. Looking ahead, the company looks forward to working closely with its investors to integrate deeply into Nantong’s robust biopharmaceutical ecosystem. Together, we aim to foster new quality productive forces and accelerate the translation of cutting-edge innovations to benefit patients worldwide.